Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Clinical research

Leishmania antigen discovery raises vaccine hopes

Vaccination with an antigen from the Leishmania parasite, which is spread by sandflies, produced a robust immune response in mice and humans.

Researchers have identified a cross-species Leishmania antigen called PEPCK that  could result in a cross-species vaccine against the Leishmaniasis. In the image, a sandfly, which is responsible for carrying the Leishmania parasite

Source: James Gathany / CDC

Sandflies spread Leishmaniasis through infected bites, affecting 12 million people a year

Leishmaniasis is an infectious disease that affects more than 12 million people and is spread in the bites of sandflies carrying Leishmania parasites. Infected people often recover and are subsequently resistant to reinfection, suggesting vaccination is feasible, but efforts have so far failed to yield a vaccine that gives long-term immunity. 

A team of international researchers report that they have identified a cross-species Leishmania antigen called PEPCK that induces a robust immune response in both mice and humans. In mice, vaccination with PEPCK led to long-lasting protection against two different Leishmania

Writing in Science Translational Medicine (online, 21 October 2015)[1], the researchers say the finding raises the “real possibility” of developing a cross-species vaccine against the disease.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20069613

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Chronotherapeutics

    Chronotherapeutics

    Chronotherapeutics discusses the pharmaceutical and therapeutic implications associated with biological clocks in humans.

    £38.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Researchers have identified a cross-species Leishmania antigen called PEPCK that  could result in a cross-species vaccine against Leishmaniasis. In the image, a sandfly, which is responsible for carrying the Leishmania parasite

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.